Table 4 Comparison of patient characteristics during totally implantable central venous access ports removal
Characteristics | Complete removal (Group N, n = 90) | Stuck fragment (Group S, n = 8) | p-value |
|---|---|---|---|
Sex | 0.048 | ||
Male | 55 (61.1%) | 8 (100.0%) | |
Female | 35 (38.9%) | 0 (0.0%) | |
Age at TICVAP insertion (months) | 85.0 [17.0;144.0] | 37.5 [31.5;57.0] | 0.357 |
Body weight at TICVAP insertion (kg) | 24.6 [11.7;48.0] | 17.0 [15.2;19.1] | 0.206 |
Age at TICVAP removal (months) | 110.0 [40.0;163.0] | 90.0 [84.5;117.5] | 0.922 |
Body weight at TICVAP removal (kg) | 32.0 [16.5;50.0] | 32.1 [27.1;43.2] | 0.704 |
Indwell duration of TICVAP (months) | 10.5 [ 5.0;20.0] | 54.5 [52.0;60.0] | < 0.001 |
Body weight change during indwell (kg) | 3.5 [ 1.2; 7.5] | 12.9 [12.2;17.6] | < 0.001 |
Follow-up duration (months) | 86.5 [44.0;100.0] | 91.0 [80.0;102.5] | 0.399 |
Diagnosis | < 0.001 | ||
Acute leukemia | 23 (25.6%) | 8 (100.0%) | |
Remaining diagnosesa | 67 (74.4%) | 0 (0.0%) | |
Platelet count at TICVAP insertion (103/ul) | 294.5 [182.0;376.0] | 71.5 [19.0;102.0] | < 0.001 |
TICVAP insertion indication | 0.713 | ||
Chemotherapy | 73 (81.1%) | 8 (100.0%) | |
Intravenous therapies | 13 (14.4%) | 0 (0.0%) | |
Nutritional support | 4 (4.4%) | 0 (0.0%) | |
TICVAP insertion site | 0.534 | ||
Left subclavian vein | 63 (70.0%) | 8 (100.0%) | |
Right subclavian vein | 19 (21.1%) | 0 (0.0%) | |
Right internal jugular vein | 4 (4.4%) | 0 (0.0%) | |
Left internal jugular vein | 3 (3.3%) | 0 (0.0%) | |
Femoral vein | 1 (1.1%) | 0 (0.0%) | |
TICVAP insertion site | |||
Left subclavian vein | 63 (70.0%) | 8 (100.0%) | 0.102 |
Remaining insertion sitesb | 27 (30.0%) | 0 (0.0%) | |
TICVAP catheter size | 0.568 | ||
5 Fr | 22 (24.4%) | 2 (25.0%) | |
6.5 Fr | 62 (68.9%) | 5 (62.5%) | |
8 Fr | 6 (6.7%) | 1 (12.5%) | |
TICVAP catheter material | 1.000 | ||
Polyurethane | 22 (24.4%) | 2 (25.0%) | |
Silicon | 68 (75.6%) | 6 (75.0%) | |